Analysts Forecast 25% Upside For PBE
May 08, 2017 at 08:58 AM EDT
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the PowerShares Dynamic Biotechnology & Genome Portfolio ETF (PBE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $53.51 per unit.